CDIO vs HLIO vs EXAS vs NTRA vs TMDX

For growth investors, Cardio Diagnostics Holdings, Inc.

(CDIO) is the stronger pick with 104. 5% revenue growth year-over-year, versus 4. 1% for Helios Technologies, Inc. (HLIO). TransMedics Group, Inc. (TMDX) offers the better valuation at 15. 0x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Cardio Diagnostics Holdings, Inc. (CDIO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TransMedics Group, Inc.

(TMDX) is the cheapest at 15. 0x versus Helios Technologies, Inc. at 46. 9x. On forward P/E, Helios Technologies, Inc. is actually cheaper at 26. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, TransMedics Group, Inc.

(TMDX) delivered a total return of +200. 7%, compared to -99. 4% for Cardio Diagnostics Holdings, Inc. (CDIO). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus CDIO's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Cardio Diagnostics Holdings, Inc. 's 3. 00β — meaning CDIO is approximately 2392% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Cardio Diagnostics Holdings, Inc. (CDIO) carries a lower debt/equity ratio of 10% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cardio Diagnostics Holdings, Inc.

(CDIO) is pulling ahead at 104. 5% versus 4. 1% for Helios Technologies, Inc. (HLIO). On earnings-per-share growth, the picture is similar: TransMedics Group, Inc. grew EPS 382. 2% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, CDIO leads at 238. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TransMedics Group, Inc.

(TMDX) is the more profitable company, earning 31. 4% net margin versus -240. 3% for Cardio Diagnostics Holdings, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMDX leads at 17. 9% versus -239. 8% for CDIO. At the gross margin level — before operating expenses — CDIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Helios Technologies, Inc.

(HLIO) trades at 26. 9x forward P/E versus 582. 8x for Exact Sciences Corporation — 555. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMDX: 98. 6% to $144. 75.

In this comparison, HLIO (0.

5% yield) pays a dividend. CDIO, EXAS, NTRA, TMDX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 3. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, CDIO: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDIO (Healthcare) and HLIO (Industrials) and EXAS (Healthcare) and NTRA (Healthcare) and TMDX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CDIO is a small-cap high-growth stock; HLIO is a small-cap quality compounder stock; EXAS is a mid-cap high-growth stock; NTRA is a mid-cap high-growth stock; TMDX is a small-cap high-growth stock. HLIO pays a dividend while CDIO, EXAS, NTRA, TMDX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.